You can read Premium News stories in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.
19 May 2020
Acquisitions lifted sales at Taisho Pharmaceutical’s Self-Medication division by 22.2% to JPY220 billion (USD2.04 billion) in the 12 months ended 31 March 2020.
17 February 2020
Acquisitions lifted sales at Taisho Pharmaceutical’s Self-Medication division by 14.5% to JPY158 billion (USD1.42 billion) in the nine months ended 31 December 2019.
4 October 2019
Taisho Pharmaceutical has signed an exclusive Japanese licensing agreement for MOB-015, Moberg Pharma's novel topical terbinafine formulation for treating nail fungus.
2 August 2019
Taisho Pharmaceutical expects its Self-Medication sales to increase by a quarter in the 12 months ended 31 March 2020 following recent acquisitions.
2 July 2019
Boiron has criticised a French recommendation on homoeopathy, Taisho Pharmaceutical has completed its planned acquisition of UPSA, and BioGaia has announced a deal with Abbott in Uruguay.
21 May 2019
Taisho Pharmaceutical has increased its stake in Vietnam's Duoc Hau Giang (DHG) Pharmaceutical to 51.01%. The Japanese company said DHG was now a consolidated subsidiary.
17 May 2019
Japan's Taisho Pharmaceutical reported Self-Medication sales down by 2.1% in the 12 months ended 31 March 2019, as it prepares to acquire Bristol-Myers Squibb's French consumer healthcare business UPSA.
4 February 2019
Japan's Taisho Pharmaceutical has reported falling Self-Medication sales at home and overseas, as it prepares to acquire Bristol-Myers Squibb's French consumer healthcare business UPSA.
19 December 2018
Japan's Taisho Pharmaceutical is set to acquire Bristol-Myers Squibb's French consumer healthcare business UPSA for USD1.6 billion.